Larcher Alessandro, Trudeau Vincent, Dell'Oglio Paolo, Tian Zhe, Boehm Katharina, Fossati Nicola, Capitanio Umberto, Briganti Alberto, Montorsi Francesco, Karakiewicz Pierre
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Division of Oncology, Unit of Urology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada; Department of Urology, University of Montreal Health Center, Montreal, QC, Canada.
Urology. 2017 Apr;102:130-137. doi: 10.1016/j.urology.2016.08.069. Epub 2016 Nov 21.
To predict the risk of cancer-specific mortality (CSM) or other-cause mortality (OCM) for T1 kidney cancer patients, aiming at identifying those who would benefit from surgery over observation.
Overall, 11,192 T1 kidney cancer patients treated with surgery or observation in the Surveillance, Epidemiology, and End Results-Medicare database were assessed. A competing risk regression (CRR) model was fitted to predict CSM and OCM after surgery or observation. Covariates consisted of age, gender, race, Charlson comorbidity index (CCI), history of acute kidney injury or chronic kidney disease, tumor size, and year of diagnosis.
At a median follow-up of 64 months, the 5-year rates of CSM and OCM were 6.7% and 24%, respectively. At CRR predicting CSM, surgery (hazard ratio [HR] 0.46; P < .0001) and year of diagnosis (HR 0.96; P < .0001) were associated with lower CSM risk. Conversely, age (HR 1.05; P < .0001), CCI (HR 1.07; P < .0001), and tumor size (HR 1.03; P < .0001) were associated with higher CSM risk. At CRR predicting OCM, surgery (HR 0.66; P < .0001), female gender (HR 0.83; P < .0001), Other race (HR 0.82; P < .0001), and year of diagnosis (HR 0.95; P < .0001) were associated with lower OCM risk. Conversely, age (HR 1.06; P < .0001), African American race (HR 1.16; P < .01), CCI (HR 1.17; P < .0001), and acute kidney injury or chronic kidney disease (HR 1.35; P < .0001) were associated with higher OCM risk.
The benefit of surgery over observation was more pronounced in younger and healthier patients with larger tumors. The proposed model can aid in clinical decision-making, providing crucial information on CSM and OCM risk after either treatment modality.
预测T1期肾癌患者的癌症特异性死亡率(CSM)或其他原因死亡率(OCM),旨在识别那些相较于观察而言能从手术中获益的患者。
总体评估了监测、流行病学和最终结果-医疗保险数据库中11192例接受手术或观察治疗的T1期肾癌患者。采用竞争风险回归(CRR)模型预测手术或观察后的CSM和OCM。协变量包括年龄、性别、种族、Charlson合并症指数(CCI)、急性肾损伤或慢性肾病病史、肿瘤大小和诊断年份。
中位随访64个月时,CSM和OCM的5年发生率分别为6.7%和24%。在预测CSM的CRR中,手术(风险比[HR] 0.46;P <.0001)和诊断年份(HR 0.96;P <.0001)与较低的CSM风险相关。相反,年龄(HR 1.05;P <.0001)、CCI(HR 1.07;P <.0001)和肿瘤大小(HR 1.03;P <.0001)与较高的CSM风险相关。在预测OCM的CRR中,手术(HR 0.66;P <.0001)、女性(HR 0.83;P <.0001)、其他种族(HR 0.82;P <.0001)和诊断年份(HR 0.95;P <.0001)与较低的OCM风险相关。相反,年龄(HR 1.06;P <.0001)、非裔美国人种族(HR 1.16;P <.01)、CCI(HR 1.17;P <.0001)以及急性肾损伤或慢性肾病(HR 1.35;P <.0001)与较高的OCM风险相关。
对于年龄较轻、健康状况较好且肿瘤较大的患者,手术相较于观察的益处更为明显。所提出的模型有助于临床决策,为两种治疗方式后的CSM和OCM风险提供关键信息。